

## “Ostial Lesion of the Left Main Coronary Artery: PCI vs. CABG?”—A Case Report and Literature Review

Driss Britel<sup>2</sup>, Mehdi Moujahid<sup>1\*</sup>, Laktib Nabil<sup>2</sup>, Youssef Fihri<sup>2</sup>, Soumia Faïd<sup>2</sup>, Hicham Faliouni<sup>2</sup>, Najat Mouine<sup>1</sup>, Ilyasse Asfalou<sup>3</sup>, Zouhair Lakhal<sup>2</sup>, Aatif Benyass<sup>4</sup>

<sup>1</sup>Clinical Cardiology Department, Military Hospital Mohamed V, Rabat, Morocco, Rabat, Morocco

<sup>2</sup>Cardiac Catheterization Unit, Military Hospital Mohamed V, Rabat, Morocco, Rabat, Morocco

<sup>3</sup>Non-invasive Cardiology Department, Military Hospital Mohamed V, Rabat, Morocco, Rabat, Morocco

<sup>4</sup>Cardiology Center, Military Hospital Mohamed V, Rabat, Morocco, Rabat, Morocco

DOI: <https://doi.org/10.36347/sasjm.2024.v10i10.050>

Received: 17.09.2024 | Accepted: 22.10.2024 | Published: 25.10.2024

\*Corresponding author: Mehdi Moujahid

Clinical Cardiology Department, Military Hospital Mohamed V, Rabat, Morocco, Rabat, Morocco

### Abstract

### Case Report

For many years, coronary artery bypass grafting has been the primary method for revascularizing significant left main coronary artery disease. However, recent advancements in percutaneous coronary intervention with drug-eluting stents have proven to be a viable and effective alternative to coronary artery bypass grafting for treating this condition. In this report, we present a case of a patient with ischemic heart disease and severe left ventricular dysfunction. Coronary angiography revealed a lesion at the ostial left main coronary artery. Following successful primary angioplasty and the placement of a drug-eluting stent, the patient's left ventricular ejection fraction significantly improved from 26% to 59%, indicating a significant enhancement in cardiac function post-procedure.

**Keywords:** Left main coronary artery revascularization, improvement in cardiac function, percutaneous coronary intervention, coronary artery bypass grafting, lesion of the ostial left main coronary artery.

Copyright © 2024 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.


## INTRODUCTION

Left main coronary artery (LMCA) disease, which significantly impacts heart muscle function and heightens cardiovascular risks, necessitates revascularization when stenosis reaches 50% or more, as per guidelines [1, 2]. Traditionally, coronary artery bypass grafting (CABG) has been the preferred treatment [3]. However, recent advancements in percutaneous coronary intervention (PCI) provide a viable alternative, contingent on clinical and anatomical considerations [4, 5]. We present a case of a 70-year-old patient who underwent angioplasty at the ostium of the left main coronary artery, achieving a favorable clinical outcome.

## CASE PRESENTATION


A 70-year-old male with a significant medical history, including poorly controlled type 2 diabetes mellitus (HbA1c 9.9%) and a history of smoking cessation 20 years ago, presented with worsening dyspnea at rest, progressing to NYHA class IV heart failure symptoms. He also reported orthopnea, paroxysmal nocturnal dyspnea, and epigastric pain. On initial examination, his blood pressure was 97/65 mmHg, heart rate 90 bpm, and oxygen saturation 95%. Lung auscultation revealed bilateral lower and mid-field crackles, indicating pulmonary congestion. An electrocardiogram (Figure 1) showed sinus rhythm with a mean heart rate of 90 bpm, normal axis, poor R-wave progression, negative T waves in the anteroseptal leads (V1, V2, V3), and flat T waves in D1 and aVL.

**Citation:** Driss Britel, Mehdi Moujahid, Laktib Nabil, Youssef Fihri, Soumia Faïd, Hicham Faliouni, Najat Mouine, Ilyasse Asfalou, Zouhair Lakhal, Aatif Benyass. “Ostial Lesion of the Left Main Coronary Artery: PCI vs. CABG?”—A Case Report and Literature Review. SAS J Med, 2024 Oct 10(10): 1267-1273.



**Figure 1: The EKG shows negative T waves in the anteroseptal leads, poor R-wave progression in the same territory, and flat T waves in D1 and aVI**


The chest X-ray (Figure 2) revealed cardiomegaly, bilateral alveolar interstitial syndrome, and prominent Kerley B lines.



**Figure 2: Chest X-ray illustrating bilateral alveolar-interstitial syndrome**

Laboratory investigations revealed elevated troponin levels at 14 ng/ml, elevated HbA1c levels at 10%, indicating poorly controlled diabetes, and elevated LDL cholesterol at 1.01 g/l. Echocardiography (Figure 3) performed at admission in March 2023 showed a dilated left ventricle without hypertrophy. It also demonstrated segmental kinetic disorders, including


akinesia of the inferoseptal, inferior, anterolateral, and anterior walls and hypokinesia of the other walls. Additionally, there was severe global systolic dysfunction, characterized by a left ventricular ejection fraction (LVEF) of 26%, a dilated left atrium, moderate secondary mitral insufficiency, elevated pulmonary artery pressure, and a dilated inferior vena cava.



**Figure 3: Echocardiography showing a dilated left ventricle with severe global systolic dysfunction (LVEF of 26%) and moderate secondary mitral insufficiency**

Coronary angiography (Figure 4) performed after clinical improvement revealed severe stenosis (70%–90%) at the ostium of the left main coronary artery, necessitating urgent intervention. Successful

percutaneous coronary intervention (PCI) with drug-eluting stent placement was conducted at the stenotic lesion, achieving optimal angiographic results and restoring coronary flow.




**Figure 4: Steps of angioplasty for a lesion at the left main coronary artery ostium**

The treatment plan included oxygen therapy, intravenous diuretics for volume management,

vasodilators to reduce afterload, and dual antiplatelet therapy (DAPT) following PCI. Additionally, a high-

intensity statin was initiated to manage dyslipidemia. Upon discharge, the patient was prescribed heart failure therapy. They are now attending regular cardiology follow-ups every three months to monitor clinical progress, adjust medical therapy as needed, and assess

cardiac function through repeat echocardiography. The most recent ultrasound (Figure 5) in April 2024 showed a notable improvement in the LVEF, which increased from 26% to 59%.



**Figure 5: Recent echocardiography demonstrates an improvement in the left ventricular ejection fraction (LVEF), increasing from 26% to 59% following revascularization**

## DISCUSSION

### LATEST EVIDENCE COMPARING PCI AND CABG FOR LMCA DISEASE [6]

Several randomized controlled trials (RCTs) have compared PCI using early-generation drug-eluting stents (DES) with CABG for treating LMCA disease, showing similar clinical outcomes between the two methods [6-8]. Notably, the EXCEL (Evaluation of Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) and NOBLE (Nordic-Baltic-British Left Main Revascularization) trials [9], were sufficiently powered to assess the efficacy of PCI with contemporary DES compared to standard CABG [6, 9-11]. However, these pivotal trials reported conflicting results: EXCEL concluded that PCI was as effective as CABG [10, 11], while NOBLE did not demonstrate non-inferiority for PCI compared to CABG [8, 12]. In clinical practice, there is a growing preference among patients and physicians for the less invasive PCI over CABG in LMCA disease [1, 13]. Despite the widespread adoption of PCI with contemporary DES for LMCA patients with varying clinical and anatomical complexities, translating trial findings into routine PCI practice without restrictions remains challenging [6].

### CURRENT REVASCULARIZATION GUIDELINES [6]

Over the past decade, clinical practice guidelines have consistently recommended CABG surgery as a Class I treatment for myocardial revascularization [6]. However, recent RCTs and registry studies increasingly support PCI as a viable alternative for selected patients with less complex LMCA disease [6, 14]. Following the EXCEL and NOBLE trials, PCI has been recognized as a suitable substitute for CABG and major changes are summarized in (table 1) [6]. The 2018 European guidelines affirmed a Class I Level of Evidence: A recommendation for CABG in all LMCA disease patients, regardless of anatomical complexity [15, 16]. PCI is recommended as Class I, IIa, or III based on the SYNTAX score, which assesses CAD complexity [6]. The 2021 American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions guideline assigns a Class IIa indication (Level of Evidence: B nonrandomized) to PCI when comparable revascularization outcomes to CABG can be achieved without further categorization based on clinical and anatomical risk profiles [17, 18].

**Table 1: Recent Updates to PCI Recommendation Guidelines for LMCA Disease [6]**

Guidelines	Class of Recommendation	Level of Evidence
Pre-EXCEL and NOBLE		
2014 ESC/EACTS [6,19]	I: LMCA disease with a SYNTAX score of < or = 22.	B
	IIa: LMCA disease with a SYNTAX score of 23–32.	
	III: LMCA disease with a SYNTAX score of > or = 33.	
2014 ACC/AHA [6,20]	IIa: For SIHD patients when both of the following conditions are present: Anatomic conditions are associated with a low risk of PCI procedural complications and a high likelihood of good long-term outcomes (e.g., a low SYNTAX score of < or = 22, ostial or trunk LMCA stenosis). Clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g., STS-predicted risk of operative mortality >5%).	B
	IIb: For SIHD patients when both of the following conditions are present: Anatomic conditions associated with a low-to-intermediate risk of PCI procedural complications and an intermediate-to-high likelihood of good long-term outcome (e.g., low-intermediate SYNTAX score <33, distal bifurcation LMCA stenosis). Clinical characteristics that predict an increased risk of adverse surgical outcomes (e.g., moderate-to-severe chronic obstructive pulmonary disease, disability from previous stroke, or previous cardiac surgery; STS-predicted risk of operative mortality >2%).	
	III: For SIHD patients (vs performing CABG) with unfavorable anatomy for PCI who are good candidates for CABG.	
Post-EXCEL and NOBLE		
2018 ESC/EACTS [6,16]	I: LMCA disease with a SYNTAX score of < or = 22.	A
	IIa: LMCA disease with a SYNTAX score of 23–32.	
	III: LMCA disease with a SYNTAX score of > or = 33.	
2021 ACC/AHA [6,18]	IIa: For selected patients with SIHD and significant LMCA disease, where PCI can provide revascularization equivalent to CABG, PCI is a reasonable option to improve survival.	B

ACC = American College of Cardiology; AHA = American Heart Association; EACTS = European Association for Cardio-Thoracic Surgery; ESC = European Society of Cardiology; SIHD = stable ischemic heart disease; STS = Society of Thoracic Surgeons [6].

**HEART TEAM APPROACH [6]**

Current guidelines highlight the importance of a multidisciplinary heart team approach in managing complex coronary artery disease (CAD), including LMCA disease [6, 18, 21, 22]. As evidence supporting PCI for specific cases of LMCA disease grows, there has been a significant increase in left main PCI procedures [6]. This trend contrasts with a gradual decline in the use of CABG, as shown by contemporary multinational registries [1, 6].

**CONCLUSIONS**

Revascularization decisions for LMCA remain challenging in clinical practice. While CABG is often considered the standard therapy, PCI offers a valuable alternative with similar survival outcomes, especially for patients with less complex coronary anatomy. Instead of viewing PCI and CABG as competing options, they should be seen as complementary strategies. The heart

team should consider factors such as coronary anatomy complexity, clinical characteristics, the expertise of the medical center and operators, and patient preferences when making treatment decisions.

**REFERENCES**

- Lee, P. H., Ahn, J. M., Chang, M., Baek, S., Yoon, S. H., Kang, S. J., ... & Park, S. J. (2016). Left main coronary artery disease: secular trends in patient characteristics, treatments, and outcomes. *Journal of the American College of Cardiology*, 68(11), 1233-1246. <https://doi.org/10.1016/j.jacc.2016.05.089>
- Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., ... & Yancy, C. W. (2011). 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart

- Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*, 58, 2550-2583. <https://doi.org/10.1161/CIR.0b013e31823ba622>
3. Rampat, R., & Hildick-Smith, D. (2015). Left Main Stem Percutaneous Coronary Intervention—Data and Ongoing Trials. *Interventional Cardiology Review*, 10(3), 132.
  4. Tan, W. A., Tamai, H., Park, S. J., Plokker, H. T., Nobuyoshi, M., Suzuki, T., ... & Ultima Investigators. (2001). Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. *Circulation*, 104(14), 1609-1614. <https://doi.org/10.1161/hc3901.096669>
  5. Park, D. W., & Park, S. J. (2017). Percutaneous coronary intervention of left main disease: Pre- and post-EXCEL and NOBLE eras. *Circulation: Cardiovascular Interventions*, 10(10), e004792. <https://doi.org/10.1161/CIRCINTERVENTIONS.117.004792>
  6. Park, S., Park, S. J., & Park, D. W. (2022). Percutaneous coronary intervention for left main coronary artery disease: Present status and future perspectives. *JACC: Asia*, 2(2), 119-138. <https://doi.org/10.1016/j.jacasi.2021.12.011>
  7. Buszman, P. E., Kiesz, S. R., Bochenek, A., Peszek-Przybyla, E., Szkrobka, I., Debinski, M., ... & Tendera, M. (2008). Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. *Journal of the American College of Cardiology*, 51(5), 538-545. <https://doi.org/10.1016/j.jacc.2007.09.054>
  8. Holm, N. R., Mäkikallio, T., Lindsay, M. M., Spence, M. S., Erglis, A., Menown, I. B., ... & Anttila, V. (2020). Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. *The Lancet*, 395(10219), 191-199. [https://doi.org/10.1016/S0140-6736\(19\)32972-1](https://doi.org/10.1016/S0140-6736(19)32972-1)
  9. Dąbrowski, E. J., Kożuch, M., & Dobrzycki, S. (2022). Left main coronary artery disease—Current management and future perspectives. *Journal of Clinical Medicine*, 11(19), 5745. <https://doi.org/10.3390/jcm11195745>
  10. Stone, G. W., Sabik, J. F., Serruys, P. W., Simonton, C. A., Généreux, P., Puskas, J., ... & Kappetein, A. P. (2016). Everolimus-eluting stents or bypass surgery for left main coronary artery disease. *New England Journal of Medicine*, 375(23), 2223-2235. <https://doi.org/10.1056/NEJMoa1610227>
  11. Stone, G. W., Kappetein, A. P., Sabik, J. F., Pocock, S. J., Morice, M. C., Puskas, J., ... & Serruys, P. W. (2019). Five-year outcomes after PCI or CABG for left main coronary disease. *New England Journal of Medicine*, 381(19), 1820-1830. <https://doi.org/10.1056/NEJMoa1909406>
  12. Mäkikallio, T., Holm, N. R., Lindsay, M., Spence, M. S., Erglis, A., Menown, I. B., ... & Christiansen, E. H. (2016). Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *The Lancet*, 388(10061), 2743-2752. [https://doi.org/10.1016/S0140-6736\(16\)32052-9](https://doi.org/10.1016/S0140-6736(16)32052-9)
  13. Kataruka, A., Maynard, C. C., Kearney, K. E., Mahmoud, A., Bell, S., Doll, J. A., ... & Hira, R. S. (2020). Temporal trends in percutaneous coronary intervention and coronary artery bypass grafting: insights from the Washington cardiac care outcomes assessment program. *Journal of the American Heart Association*, 9(11), e015317. <https://doi.org/10.1161/JAHA.119.015317>
  14. Korean Circulation Journal. (2019). Percutaneous coronary intervention and coronary artery bypass grafting for the treatment of left main coronary artery disease. *Korean Circulation Journal*, 49(5), 369–383. <https://doi.org/10.4070/kcj.2019.0112>
  15. Topol, E. J., & Teirstein, P. S. (2019). *Textbook of interventional cardiology* (8th ed.). Elsevier. ISBN 9780323568142; Doi: 2019943784.
  16. Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., ... & Zembala, M. O. (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. *European heart journal*, 40(2), 87-165. <https://doi.org/10.1093/eurheartj/ehy394>
  17. Almoghairi, A., Al-Asiri, N., Al Johani, K., AlSaleh, A., & Alqahtani, N. G. (2023). Left main percutaneous coronary revascularization. *US Cardiology Review*, 17, e09. <https://doi.org/10.15420/usc.2022.24>
  18. Lawton, J. S., Tamis-Holland, J. E., & Bangalore, S. (2022). 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 79(2), 21-129. <https://doi.org/10.1161/CIR.0000000000001039>
  19. Windecker, S., Kolh, P., & Alfonso, F. (2014). 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association of Cardio-Thoracic Surgery (EACTS). *European Heart Journal*, 35(29), 2541-2619. <https://doi.org/10.1093/eurheartj/ehu278>
  20. Fihn, S. D., Blankenship, J. C., & Alexander, K. P. (2014). 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*, 64(18), 1929-1949. <https://doi.org/10.1016/j.jacc.2014.07.017>

21. Lawton, J. S., Tamis-Holland, J. E., & Bangalore, S. (2022). 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 79(2), e21-e129.
22. Park, S. J., & Park, D. W. (2022). International variation in modality and outcomes of left main revascularisation: does it really matter?. *EuroIntervention*, 17(13), 1048. Doi: 10.4244/EIJ-E-21-00002.